报价延迟最少15分钟:2025/11/16 13:31 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.19 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.28/--
|
|
企业价值
24.53M
|
| 资产负债 |
|
每股账面净值
0.11
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 13:31 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. Itfocuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity. |
